🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell

    Sanofi Pasteur

    Cholera

    approved mab completed

    1 trial

  2. Short Cycle Antiretroviral Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    approved other completed

    1 trial

  3. Silver Sulfadiazine

    United Therapeutics Europe Ltd

    Superficial Partial Thickness Burn

    approved small molecule terminated

    1 trial

  4. Sodium Chloride Fresenius Kabi Italia 0,9 % Solution for infusion, MabThera 500 mg concentrate for solution for infusion

    Disc Medicine

    Systemic sclerosis

    approved small molecule active

    1 trial

  5. Solriamfetol

    Axsome Therapeutics

    Excessive Daytime Sleepiness

    approved small molecule completed

    1 trial

  6. Solriamfetol 75 MG

    Axsome Therapeutics

    Insomnia

    approved small molecule completed

    1 trial

  7. Solriamfetol Oral Tablet

    Axsome Therapeutics

    Excessive Sleepiness

    approved small molecule terminated

    1 trial

  8. Sparsentan

    Travere Therapeutics

    Proteinuria

    approved small molecule active

    1 trial

  9. Spesolimab

    Boehringer Ingelheim

    Generalized Pustular Psoriasis

    approved small molecule active

    3 trials

  10. Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum

    United Therapeutics Europe Ltd

    Frostbite

    approved small molecule active

    1 trial

  11. Stereotactic Radiation Therapy

    GT Biopharma

    Glioblastoma

    approved other terminated

    1 trial

  12. Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution

    HALOZYME THERAPEUTICS, INC.

    Dehydration

    approved small molecule terminated

    1 trial

  13. Subcutaneous Treprostinil

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    approved small molecule terminated

    1 trial

  14. Subcutaneous depot medroxyprogesterone acetate

    Protara Therapeutics

    Contraception

    approved small molecule completed

    1 trial

  15. Sublingual film containing Igalmi

    BioXcel Therapeutics

    Bipolar Disorder

    approved small molecule completed

    1 trial

  16. Sugammadex hameln 100 mg/ml oplossing voor injectie, Naloxon HCl Accord 0,4 mg/ml, oplossing voor injectie / infusie in een voorgevulde spuit, ANEXATE 0,5 mg/5 ml, solution injectable (I.V.), REMIMAZOLAM , Sufentanil Viatris 5 microgram/ml oplossing voor injectie, Esmeron 10 mg/ml, oplossing voor injectie

    Disc Medicine

    General anesthesia

    approved small molecule active

    1 trial

  17. Sulfadoxine-pyrimethamine

    United Therapeutics Europe Ltd

    Malaria (Uncomplicated)

    approved small molecule completed

    1 trial

  18. Surabgene Lomparvovec (ABBV-RGX-314), Lucentis 10 mg/ml solution for injection in pre-filled syringe, Surabgene Lomparvovec (ABBV-RGX-314)

    AbbVie Deutschland GmbH & Co. KG

    Neovascular age-related macular degeneration

    approved small molecule active

    1 trial

  19. Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)

    GT Biopharma

    Glioblastoma

    approved other active

    1 trial

  20. TIMOFEROL 50 mg, comprimé enrobé, TIMOFEROL, gélule, FERRIC CARBOXYMALTOSE

    Pari Pharma GmbH

    Women who delivered by caesarean and have a moderate postpartum iron deficiency anaemia defined by 8.0 g/dL ≤ postoperative Hb level ≤ 10.0 g/dL within 72h after delivery and a ferritinemia ≤ 100 ng/mL OR transferrin saturation ≤ 20% (Measured after postoperative Hb level measurement)

    approved small molecule active

    1 trial

  21. TRALOKINUMAB, The placebo presentation is a pre-filled syringe containing the same excipients in the same amounts as the IMP.

    LEO Pharma A/S

    Atopic dermatitis and moderate-to severe atopic hand eczema

    approved small molecule active

    1 trial

  22. Tadalafil

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    approved small molecule terminated

    1 trial

  23. Telavancin

    Theravance Biopharma Ireland Umited

    End-Stage Renal Disease

    approved small molecule completed

    1 trial

  24. Temozolomide

    Monte Rosa Therapeutics

    Brain Neoplasms, Malignant, Primary

    approved small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources